MedPath

BEOVU

BEOVU

Approved
DIN Number

02496976

Drug Class

Human

Market Date

May 15, 2020

Company
HC

novartis pharmaceuticals canada inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02496976
AIG Number0162094001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
S01LA06 BROLUCIZUMAB
Product Specifications
Dosage FormSolution
Route of AdministrationIntravitreal
AHFS Classification52:92.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

BROLUCIZUMABActive
Strength: 6 MG / 0.05 ML
Monograph: BROLUCIZUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.